Modulating the Tumor Microenvironment in Metastatic Osteosarcoma: Palladia/Losartan/Ladarixin Combination Therapy
condition(s)
osteosarcoma
eligibility information
Enrollment Deadline
Enrollment ends July 7, 2022
Enrollment ends July 7, 2022